	US 12,343,407 B2
	Inflammasome-targeted RNA interference approach to treating kidney injury and disease
Michael R. McDevitt, New York, NY (US); and David A. Scheinberg, New York, NY (US)
Assigned to Memorial Sloan Kettering Cancer Center, New York, NY (US)
Appl. No. 17/434,317
Filed by MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US)
PCT Filed Feb. 26, 2020, PCT No. PCT/US2020/019987 § 371(c)(1), (2) Date Aug. 26, 2021, PCT Pub. No. WO2020/176679, PCT Pub. Date Sep. 3, 2020.
Claims priority of provisional application 62/811,498, filed on Feb. 27, 2019.
Prior Publication US 2022/0168444 A1, Jun. 2, 2022
Int. Cl. A61K 47/69 (2017.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); A61P 13/12 (2006.01); G01N 33/68 (2006.01); C12Q 1/68 (2018.01)

CPC A61K 47/6923 (2017.08) [A61K 31/713 (2013.01); A61K 45/06 (2013.01); A61K 47/6929 (2017.08); A61P 13/12 (2018.01); G01N 33/6893 (2013.01); G01N 2333/705 (2013.01); G01N 2800/347 (2013.01); G01N 2800/52 (2013.01)]

25 Claims

1. A pharmaceutical composition, comprising:

a sidewall ammonium-functionalized carbon nanotube (fCNT), and

an effective amount of at least one Nlrp3 siRNA that inhibits NLR pyrin domain-containing protein 3 (NLRP3) expression levels or activity in a cell, wherein the at least one Nlrp3 siRNA comprises a sense strand and an antisense strand, wherein the antisense strand comprises SEQ ID NO:4;

wherein the fCNT is non-covalently conjugated to the at least one Nlrp3 siRNA.